Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Rapalogs Potential as Practical Alternatives to Rapamycin.

Literature DB >> 31223435

Rapalogs Potential as Practical Alternatives to Rapamycin.

Ahmed F Abdel-Magid¹.

Abstract

Year: 2019 PMID： 31223435 PMCID： PMC6580369 DOI： 10.1021/acsmedchemlett.9b00215

Source DB: PubMed Journal: ACS Med Chem Lett ISSN： 1948-5875 Impact factor: 4.345

× No keyword cloud information.

4 in total

Review 1. Toward rapamycin analog (rapalog)-based precision cancer therapy.

Authors: Ling-hua Meng; X F Steven Zheng
Journal: Acta Pharmacol Sin Date: 2015-08-24 Impact factor: 6.150

Review 2. Rapalogs and mTOR inhibitors as anti-aging therapeutics.

Authors: Dudley W Lamming; Lan Ye; David M Sabatini; Joseph A Baur
Journal: J Clin Invest Date: 2013-03-01 Impact factor: 14.808

Review 3. Review of PI3K/mTOR Inhibitors Entering Clinical Trials to Treat Triple Negative Breast Cancers.

Authors: Amélie Fouqué; Mickael Jean; Pierre van de Weghe; Patrick Legembre
Journal: Recent Pat Anticancer Drug Discov Date: 2016 Impact factor: 4.169

Review 4. New perspectives on mTOR inhibitors (rapamycin, rapalogs and TORKinibs) in transplantation.

Authors: Matthias Waldner; Daniel Fantus; Mario Solari; Angus W Thomson
Journal: Br J Clin Pharmacol Date: 2016-03-06 Impact factor: 4.335

4 in total

3 in total

Rapalogs Potential as Practical Alternatives to Rapamycin.

Review 1. Toward rapamycin analog (rapalog)-based precision cancer therapy.

Review 2. Rapalogs and mTOR inhibitors as anti-aging therapeutics.

Review 3. Review of PI3K/mTOR Inhibitors Entering Clinical Trials to Treat Triple Negative Breast Cancers.

Review 4. New perspectives on mTOR inhibitors (rapamycin, rapalogs and TORKinibs) in transplantation.

Review 1. Rapamycin in Cerebral Cavernous Malformations: What Doses to Test in Mice and Humans.

Review 2. Translational control in cell ageing: an update.

Review 3. Recent advances and limitations of mTOR inhibitors in the treatment of cancer.